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Original Article
Effect of the celexoxib in microscopic changes of the esophageal
mucosal of rats induced by esofagojejunostomy
Efeito do celecoxibe nas alterações microscópicas da mucosa esofágica de ratos
causadas por esofagojejunostomia
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A B S T R A C T
Objective: To evaluate the protective effect of celecoxib in the esophageal mucosa in rats undergoing esofagojejunostomy.
Methods: Sixty male Wistar rats from the vivarium of the University of Health Sciences of Alagoas were used for the experiment.
The animals were divided into four groups: Group I, 15 rats undergoing esofagojejunostomy with the use of celecoxib postoperatively;
Group II, 15 rats undergoing esofagojejunostomy without the use of celecoxib; Group III, 15 rats undergoing celiotomy with bowel
manipulation; and Group IV, 15 rats without surgery and using celecoxib. The observation period was 90 days. After the death of the
animals, the distal segment of the esophagus was resected and sent for microscopic analysis. Results: esofagojejunostomy caused
macroscopic and microscopic esophagitis. Esophagitis was equal in both groups I and II. In groups III and IV esophageal lesions were
not developed. Conclusions: celecoxib had neither protective nor inducing effect on  esophagitis, but had a protective effect on
dysplasia of the animals of group I.
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INTRODUCTION
The gastroesophageal reflux disease (GERD) has greatmedical and social importance due to its high and
increasing incidence and to its symptoms of varying
intensity, manifested by prolonged time and often
decreasing patients’ quality of life1. It is a common
condition that affects around 20-50% of adults in Western
countries 2.
Isolated heartburn was observed in 17.8% of
adults suffering from this disease. In the West, the
incidence of GERD is estimated between 10 and 20% in
adults 3.
GERD is defined as a condition that develops
when the reflux of stomach contents into the esophagus
causes symptoms and / or complications 4,5. The prevalence
of GERD was evaluated and the weekly occurrence of
symptoms of heartburn and acid regurgitation was
observed. These symptoms were present in approximately
2% of children between three and nine years old and
between 5% and 8% in children between ten and 17
years.
In the U.S., more than 50% of adults reported
heartburn at least once a week and one fourth made use
of antiacid medication  at least three times a week. In
Brazil, in a population study with national coverage,
heartburn (once a week), was present in 4.6% of the
sample. When the incidence of heartburn was once or twice
a week, prevalence was 7.3%. It is estimated that
approximately 12% of the population has GERD, without
including those with atypical manifestations, which should
certainly increase this number 6.
In 1893, the German chemist Felix Hoffman
discovered the anti-inflammatory agent aspirin, widely
prescribed and used worldwide. Its mechanism of action
was elucidated only in 1971, when John Vane proposed
that anti-inflammatory drugs, like aspirin, suppress
inflammation by inhibiting the enzyme cyclooxygenase
(COX), thereby preventing the synthesis of prostaglandins
7. COX catalyzes  prostaglandins, also known as
Prostaglandin   Synthetase or Prostaglandin Endoperoxide
Synthase. These prostaglandins were isolated in 1976
and cloned in 1988. In 1991 a gene encoding a second
isoform of the enzyme was identified, then denominated
cyclooxygenase-2 (COX-2). It is known nowadays that
both genes express two very similar distinct isoforms of
the enzyme: cyclooxygenase-1 (COX1) and
cyclooxygenase-2 (COX-2). The two isoforms have simi-
lar protein structures and catalyze essentially the same
reaction 8-13.
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The combination of these agents produced a new
generation of anti-inflammatory drugs (selective COX2
inhibitors), called the coxibs 14,15.
More recently, new motivations for clinical use
and research were found with the description of a third
cyclooxygenase variant ,called COX3 16. Studies have
demonstrated that the concentration of COX-2 is elevated
both in esophagitis , in Barrett’s esophagus and in
esophageal adenocarcinoma 17-19.
Although substances such as COX2 and others
have important roles in several known anti-inflammatory
events,  the pathogenesis of gastroesophageal reflux
disease in is still unknown. On an induced reflux esophagitis
model in rats, there was a significant increase in the
expression of COX2, indicating its important role in the
pathogenesis of esophagitis 20.
Celecoxib is a drug with anti-inflammatory and
analgesic action. Despite its effect, there is still lack of
mainly pharmacological studies investigating its actual
molecular and cellular actions, as well as its interference in
cellular metabolism, oxidative stress and the expression of
proteins linked in the development of certain diseases. This
research aimed to evaluate whether celecoxib exerts a
protective role on the esophageal mucosa of rats subjected
to esofagojejunostomy.
METHODS
From January 2009 to December 2010, we
studied 60 animals, aged between three and four months,
average weight of 350g and acclimated to the vivarium
conditions at the State University of Health Sciences of
Alagoas - UNCISAL. The project was approved by the Ethics
Committee of UNIFESP / EPM with number 1872/0.
The animals were housed, up to three animals
per cage, and were fasted for 12 hours before the operation.
The observation period for the four groups was 90 days.
Celecoxib was administered orally at a dose of 10mg/kg/
day, in agreement with other studies 21-23.
The animals were divided into four groups: Group
I, 15 rats undergoing esofagojejunostomy and receiving
celecoxib postoperatively; Group II, 15 rats  submitted to
esofagojejunostomy without the use of celecoxib; Group
III, 15 rats undergoing celiotomy with bowel loops
manipulation; Group IV, 15 rats without esofagojejunostomy
and receiving celecoxib (Table 1).
The anesthetic technique was by intraperitoneal
injection of ketamine hydrochloride (80 to 100mg/kg),
associated with 10mg/kg of xylazine for relaxation 24. All
animals were operated under aseptic, acclimated conditions
and fed ad libitum from the third postoperative day on.
The animals were submitted to antisepsis of the
abdominal wall with polyvinyl iodine polirridone and asepsis.
The median celiotomy was from the xiphoid appendix to
the middle third of the abdominal wall, including the skin,
subcutaneous tissue, muscle-aponeurotic plane and parietal
peritoneum. In groups I and II we proceeded to display,
repair and opening of 0.5 cm of jejunum 10 cm distally
from the duodenojejunal junction. The dissection of the
distal esophagus was carried out by the release of the
hepatic ligaments. With a magnifying glass with a 10x ran-
ge, we held a 1.0 cm longitudinal opening in the esophagus
and performed a lateral-lateral  esofagojejunostomy (Figu-
re 1) with a running suture of 7-0 Prolene with atraumatic
needle; we then proceeded immediately to the closing of
the muscle-aponeurotic plane with chrome 5-0 catgut and
the skin with 5-0 nylon,  both with running sutures.
In groups I and IV 10mg/kg/day of Celecoxib were
administered orally, in gavage, using a 1ml syringe, from
the third day after surgery until the day they were
euthanized.
All animals were maintained post-operatively
under the same environmental conditions. Postoperative
analgesia was made with dipyrone 20 mg by gavage for
three days. In the first 24 hours the animals received
only water ad libitum in a solution of 5% glucose. The
extruded Labina, a proper chow for this type of animal,
was initiated from the third day. The animals were
weighed fortnightly.
At the end of 90 days the animals were
euthanized with a thionembutal intraperitoneal injection
Figure 1 - Laterolateral esophagojejunal anastomosis.
Table 1 - Distribution of rats according to the procedure
and drug use.
G roup Tota l Operat ion Drug
I 15 100% 100%
II 15 100% 0%
III 15 100% 0%
IV 15 0% 100%
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at a dose of 50mg/kg followed by an intracardiac injection
of potassium chloride. The specimens were obtained (Figu-
re 2) and forwarded to the Department of Pathology,
Maceio Holy Home of Mercy, for histopathological
examination.
Macroscopic analysis was performed by
measuring the specimens, followed by longitudinal cuts in
their entire length, dehydration, paraffinization, histological
sections stained by hematoxylin and eosin, followed by
analysis with optical microscope with 10x and 40x
magnifications, made by two pathologists, without any
knowledge of the material between them.
Given the findings of our study, two statistical
evaluations were used: Fisher’s exact test in Groups I and
II, to assess the use or not of the drug , and the relative
risk,  also applied to Groups I and II, to evaluate high and
low-grade dysplasias.
RESULTS
Esophagitis with dysplasia was found in 28
animals, 13 having high-grade dysplasia and 15 low-gra-
de. The following microscopic changes were present in
group I: chronic esophagitis with high-grade dysplasia in
three animals (Figure 3), chronic esophagitis with low-gra-
de dysplasia in ten animals and adenocarcinoma in two. In
group II we found: chronic esophagitis with high-grade
dysplasia in ten animals and chronic esophagitis with low-
grade dysplasia in five. As for the outcome high-grade
dysplasia, group I had a relative risk of 0.29 (71% protective
effect – calculated by the ratio of incidences) when
compared with group II. No microscopic changes of the
esophageal mucosa were found in rats in groups III and IV.
DISCUSSION
Surgical research with laboratory animals has
expanded in recent decades due to the better support
anesthetic techniques, the sophistication of the infrastructure
equipment for continuous intraoperative monitoring and an
incessant search for models that reproduce morbid
conditions of the human species. The main focus of this
research has been to improve the knowledge of the
pathophysiological mechanisms of diseases, increase
therapeutic trials with new drugs, study biological markers,
with prospects of applicability in humans.
Of the 86 animals studied, 26 (30.2%) died
before the stipulated time for research, which we regard
as early deaths,  with the following causes: three cases of
intracavitary abscess, eight cases of aspiration, three cases
of anastomotic stenosis and in 12 cases in which we could
not find the cause.
All animals were autopsied after death. Where
the cause of death was not found, the hypothesis that the
anesthetic, muscle relaxant, or even dipyrone, had been
the cause of death has not been ruled out, since xylazine,
although inducing a rapid and effective sedation and
analgesia, can have harmful effects such as hypotension
and bradycardia.
Histopathological results confirmed the presence
of esophagitis with different degrees of dysplasia in 28
animals, 13 with high-grade dysplasia and 15 with low-
grade, and two cases of invasive adenocarcinoma.
Regarding dysplasia, the diagnosis was based on cytologic
and structural alterations proposed by Montgomery in 2002,
an algorithm that distinguishes epithelial in low or high gra-
de dysplasia. The algorithm is based on the main histological
Figure 3 - Esophagitis with high-grade dysplasia.
Figure 2 - Specimen for histopathology: dilated esophagus,
afferent and efferent loops, stomach, spleen and
esophagojejunal anastomosis.
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features found in Barrett’s esophagus 25. The cluster of glands
varied sizes and shapes with branches or cribiform
arrangements is an important architectural change.
Epithelial maturation is a key attribute for the diagnosis of
dysplasia 25,26. Dysplasia should be examined by comparing
the cells in the deeper portions of the mucosa with surface
ones. The cytological features belonging to the Montgomery
algorithm should be analyzed under the microscope in the
largest magnifications. These cells should display discrete
atypia by increased volume of their nuclei. The polarity of
the cells is also part of the Montgomery algorithm to be
studied. The polarity is normal when the nuclei are arranged
in parallel, with the largest axis perpendicular to the
basement membrane, the loss of polarity of nuclei being a
characteristic morphological attribute of high-grade
dysplasia.
A study with rats subjected to
esofagojejunostomy using a COX2 inhibitor, rofecoxib,
showed no esophageal mucosal protection. The authors
claimed that  protection does not exist in severe injuries
and suggested conducting studies with models of less severe
esophagitis 27. Yet, according to these authors 27, neither
rofecoxib nor vitamin C had a protective effect against
esophagitis in this reflux model. This seems the most plausible
answer to the result of our research, taking into account
also that Murphy et al. 27 exposed the esophageal mucosa
of their animals for only six weeks, whereas in ours the
exposure lasted for 12 weeks.
In conclusion, our study showed that celecoxib
had neither a protective nor an inducing effect on
esophagitis, but showed a protective effect in dysplasias of
the animals of group I.
R E S U M O
Objetivo: avaliar o efeito do celecoxibe como função protetora na mucosa esofágica, em ratos machos Wistar, submetidos à
esofagojejunostomia. Métodos: sessenta animais oriundos do biotério da Universidade de Ciências da Saúde de Alagoas foram
utilizados para o experimento. Os animais foram distribuídos em quatro grupos: Grupo I, 15 ratos que foram submetidos à
esofagojejustomia e que utilizaram o celecoxibe no pós-operatório, Grupo II, 15 ratos submetidos à esofagojejunostomia sem uso de
celecoxibe, Grupo III, 15 ratos submetidos à celiotomia com manipulação de alças, e Grupo IV, 15 ratos sem cirurgia e que utilizaram
celecoxibe.  O período de observação foi de 90 dias. Após a morte dos animais, o seguimento distal do esôfago foi ressecado e
enviado para análise macro e microscópicas. Resultados: a esofagojejunostomia causou esofagite macro e microscópica. A
esofagite foi igual tanto no grupo I quanto no II. Nos animais dos grupos III e IV não foram desenvolvidas lesões esofagianas.
Conclusões: o celecoxibe não teve efeito protetor nem indutor nas esofagites, mas obteve efeito protetor nas displasias dos
animais do grupo I.
Descritores: Esofagite de refluxo. Epitélio/histologia. Inflamação. Cirurgia. Ratos Wistar.
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